Field trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes.
A double blind field trial was started with a candidate anti-leprosy vaccine, Mycobacterium w as an immunotherapeutic and immunoprophylactic agent against leprosy in a highly endemic region with a prevalence rate of over 18 per 1000 population. By 31 August 1992, 224 villages have been surveyed, covering a population of 307,981 (1981 census). A total of 979 MB patients and 2801 PB patients have been registered. A total of 19,453 household contacts of leprosy patients have been examined for clinical signs of disease, of which 16,519 have received the initial dose while 10,434 have also received the booster dose of vaccine/placebo. The aims and objectives, study design of the trial, present status as well as the socio-cultural aspect involved are highlighted in this paper.
Walia
R
R
Microbiology Division, National Institute of Immunology, New Delhi, India.
Sarathchandra
K G
KG
Pandey
R M
RM
Parida
S K
SK
Zaheer
S A
SA
Kar
H K
HK
Mukherjee
A
A
Mukherjee
R
R
Talwar
G P
GP
D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000517:prevention & control* / Q000628:therapy*; D009161:Mycobacterium / Q000276:immunology
D001428:Bacterial Vaccines; D007917:Leprostatic Agents; C080550:Mycobacterium w vaccine